Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BA 015 gene therapy

Drug Profile

BA 015 gene therapy

Alternative Names: AMEP; BA-015 AMEP peptide; p-AMEP; Plasmid AMEP; Synfoldin

Latest Information Update: 09 Dec 2014

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioAlliance Pharma
  • Developer BioAlliance Pharma; Onxeo SA
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action ADAM protein inhibitors; Angiogenesis inhibitors; Gene transference; Integrin alpha 5 beta 1 inhibitors; Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malignant melanoma; Solid tumours

Most Recent Events

  • 09 Dec 2014 Discontinued - Phase-I/II for Malignant melanoma in France (IM)
  • 09 Dec 2014 Discontinued - Phase-I/II for Malignant melanoma in Slovenia (IM)
  • 01 Aug 2014 TopoTarget has merged with BioAlliance Pharma to form Onxeo SA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top